Revolution Medicines, Inc. current report, 09 July 2022

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Revolution Medicines, Inc. on July 9, 2022. The filing addresses corporate governance changes, specifically the appointment of a new director and the resignation of an existing director, effective July 12, 2022.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.

Material Changes

  • Board Resignation: Neil Exter resigned from the Board of Directors, effective July 12, 2022.
  • Board Appointment: Lorence Kim, M.D., was appointed to the Board of Directors to fill the vacancy created by Dr. Exter's resignation, effective July 12, 2022.
  • Committee Assignment: Dr. Kim will serve on the Audit Committee and has been determined to qualify as an audit committee financial expert.

Guidance, Outlook, and Compensation

The filing contains no financial guidance, outlook, or management commentary regarding business operations. It details the compensatory arrangements for the new director:

  • Initial Equity Grant: Dr. Kim received an option to purchase 36,800 shares of common stock and 10,500 restricted stock units (RSUs).
  • Vesting Schedule: The option vests in monthly installments over three years; the RSUs vest in quarterly installments over three years.
  • Cash Compensation: Dr. Kim is entitled to cash retainers as described in the Company's 2022 Proxy Statement.
  • Background: Dr. Kim previously served as CFO of Moderna, Inc. and is currently a Venture Partner at Third Rock Ventures.

Investor Verification Checklist

  • Verify the effective date of the board composition change (July 12, 2022).
  • Confirm Dr. Kim's independence status and audit committee financial expert qualification per Nasdaq standards.
  • Review the specific vesting terms of the 36,800 options and 10,500 RSUs granted to Dr. Kim.
  • Check the Company's 2022 Proxy Statement for details on the cash retainers applicable to Dr. Kim.